<DOC>
	<DOCNO>NCT01843309</DOCNO>
	<brief_summary>Purpose Invasive fungal infection cause significant morbidity mortality immunocompromised patient . Amphotericin B deoxycholate ( AmB ) polyene antifungal agent . The broad spectrum activity contribute consider gold standard antifungal therapy despite associate high incidence infusion relate adverse event . AmB exert antifungal effect bind ergosterol ; sterol similar cholesterol find fungal cell membrane . However AmB also bind cholesterol molecule mammalian cell membrane form intramembranous pore vacuole distal convolute tubule kidney produce nephrotoxic effect . Nephrotoxicity major adverse effect AmB , often limit administration full dosage ; 's manifest acute kidney injury , impaired renal concentrating ability , augment urinary potassium secretion tubular Na+/K+ ATPase , type-1 renal tubular acidosis , increase elimination potassium , magnesium wasting . Furthermore potassium depletion potentiate tubular toxicity AmB . The management potassium wasting may difficult , even high intravenous dos potassium chloride may fully effective correct hypokalemia . It probe use potassium-sparing diuretic limit electrolyte wasting patient treat AmB . In 1988 Smith et al , demonstrate amiloride well tolerate provide effective control plasma potassium patient treat AmB . This finding confirm 2001 Bearden et al . However country available commercial presentation amiloride also contain hydrochlorothiazide , limit use patient . Spironolactone act distal renal tubule competitive inhibition aldosterone , thereby block exchange sodium potassium hydrogen distal tubule collect duct . These agent produce sodium diuresis result potassium retention . There one clinical trial Ural et al , use spironolactone prevent hypokalemia twenty-six neutropenic patient AmB treatment ; demonstrate patient receive concomitant AmB spironolactone ( 100mg bid ) significantly high plasma potassium level receive AmB alone ( P=0.0027 ) require significantly less potassium supplementation maintain plasma potassium within normal range ( P=0.022 ) . Renal vasoconstriction appear play major role AmB induce reduction GFR ; recurrent ischemia may lead structural tubular damage permanent nephrotoxic effect . Aldosterone modulate tone renal vasculature . Bobadilla et al show animal model cytotoxic damage use cyclosporine ; mineralocorticoid receptor blockade spironolactone reduce structural renal damage , also prevent renal dysfunction due afferent efferent vasoconstriction . This group also show prophylactic treatment spironolactone completely prevent renal dysfunction histological sign tubular injury ischemia-reperfusion injury . And also demonstrate ability spironolactone animal model protect kidney establish ischemic insult , spironolactone administrate immediately 3h renal ischemic insult occur , reduce level sensitive biomarkers Kim-1 Hsp70 . The investigator ' hypothesis administration spironolactone patient treat AmB help maintain significantly high plasma potassium level help reduce potassium magnesium supplementation . Moreover spironolactone help reduce urinary excretion potassium . The investigator propose randomize , double blind , placebo control trial approve local ethical committee , compare efficacy security spironolactone reduce electrolytic derangement three group : AmB placebo , AmB spironolactone 100mg day , AmB spironolactone 100mg twice day . The investigator include 12 patient per group . Researchers collect daily plasma creatinine , sodium , potassium , BUN urinary potassium , well value potassium magnesium supplement administer orally parenterally . The researcher also collect 7 day urinary level NGAL , KIM-1 Hsp-70 tubular injury marker .</brief_summary>
	<brief_title>Use Spironolactone Prevention Electrolyte Abnormalities Patients Treated With Amphotericin B</brief_title>
	<detailed_description />
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Patients indication AmB treatment Patients acute kidney injury Hyperkalemia ≥5.2 Hypersensibility spironolactone HIV infection Pregnant woman Solid organ transplant Hemodynamic instability CKDEPI ≤30ml/min/1.73m3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>